Bali BioSciences is led by Zeil Rosenberg, MD, MPH, a vaccine, clinical trials and medical device expert, who has led multi-disciplinary global teams bring medical products from concept through to commercialization.
Dr. Rosenberg is Executive Director at PPD Biotech solutions, the clinical research arm of Thermo Fisher Scientific, where he focuses on bringing strategic insights to biotechnology companies around the clinical development of their new vaccines and therapeutics. Immediately prior to this he was Medical Director and Therapeutic Area Head for Vaccines at PPD AES, providing medical leadership to the Vaccine Centers of Excellence, a global network of clinical trials sites. His areas of expertise extend to digital health, medical devices and diagnostics.
Immersed in clinical trials for COVID-19 vaccines, Dr. Rosenberg has authored The COVID-19 Vaccine: An Expert's Medical Review for All, where he shares up-to-date medical knowledge about the development, safety and effectiveness of COVID-19 vaccines.
Previous to PPD, he was Vice President, Medical Affairs at Admera Health and Worldwide Business Leader and Medical Director, Immunization at Becton Dickinson & Co. for nearly 10 years where he helped develop and successfully launch a number of medical devices of global health importance.
Dr. Rosenberg received his BA in Economics at Stanford, his MD at UCSF, completed his post-graduate medical training in Medicine and Preventive Medicine at Mt. Sinai and Cornell, respectively, and received his MPH in Epidemiology at Columbia. He was selected as AAAS Science, Engineering, and Diplomacy Fellow. Dr. Rosenberg is a Fellow of the American College of Preventive Medicine, Specialty Fellow of the American Academy of Pediatrics, and Fellow of the New York Academy of Medicine.